Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $257.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Preferred Stock Liabilities rose 72.05% to $257.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $257.0 million, a 72.05% increase, with the full-year FY2024 number at $191.8 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $257.0 million for Q3 2025 at Evommune, up from $191.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $257.0 million in Q3 2025 to a low of $149.4 million in Q3 2024.